Arvinas Inc Cash Flow Conversion Efficiency
Arvinas Inc cash flow conversion efficiency. Based on the latest financial reports, Arvinas Inc (ARVN) has a cash flow conversion efficiency ratio of -0.086x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.30 Million) by net assets ($562.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arvinas Inc (2016–2025)
Cash flow conversion efficiency of Arvinas Inc from 2016 to 2025. This chart illustrates how Arvinas Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arvinas Inc (ARVN) stock price for real-time trading data and today's change.
Arvinas Inc Cash Flow Conversion Ratio Explained
Arvinas Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arvinas Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arvinas Inc ranked by their cash flow conversion efficiency. Also see Arvinas Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rainbow Tours SA
WAR:RBW
|
-0.217x |
|
Shandong Haihua Co Ltd
SHE:000822
|
0.007x |
|
Veken Elite
SHG:600152
|
0.045x |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
-0.006x |
|
POET Technologies Inc
V:PTK
|
-0.157x |
|
Grupo Supervielle SA
NYSE:SUPV
|
-0.378x |
|
Guangdong Super Telecom
SHG:603322
|
0.053x |
|
Ningbo Shenglong Automotive Powertrain System Co Ltd
SHG:603178
|
0.065x |
Annual Cash Flow Conversion Efficiency for Arvinas Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arvinas Inc from 2016 to 2025. Review ARVN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $433.80 Million | $-273.80 Million | -0.631x | -36.72% |
| 2024-12-31 | $561.70 Million | $-259.30 Million | -0.462x | +12.40% |
| 2023-12-31 | $660.00 Million | $-347.80 Million | -0.527x | -8.84% |
| 2022-12-31 | $564.90 Million | $-273.50 Million | -0.484x | -167.66% |
| 2021-12-31 | $781.70 Million | $559.40 Million | 0.716x | +612.02% |
| 2020-12-31 | $642.20 Million | $-89.76 Million | -0.140x | +22.01% |
| 2019-12-31 | $226.69 Million | $-40.63 Million | -0.179x | -51.97% |
| 2018-12-31 | $136.67 Million | $-16.12 Million | -0.118x | -100.57% |
| 2017-12-31 | $245.87K | $5.11 Million | 20.796x | +2675.61% |
| 2016-12-31 | $24.03 Million | $-19.40 Million | -0.807x | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more